Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6qc-ICG skin tolerability and intraoperative breast tumor fluorescence study
NL-OMON58321Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of 6QC-ICG in breast cancer and ductal carcinoma in situ (DCIS) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Local tolerability, Pain and itch scores and 6 more. Started Jun 2026; status: recruiting.
02
Drugs
6QC-ICG
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NL-OMON58321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58321.